Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes





Sung Hwan Lee, Sun Young Yim, Yun Seong Jeong, Qi-Xiang Li, Sang-Hee Kang, Bo Hwa Sohn, Shwetha V Kumar, Ji-Hyun Shin, You Rhee Choi, Jae-Jun Shim, Hayeon Kim, Jihoon Kim, Shin Kim, Sheng Guo, Randy L Johnson, Ahmed Kaseb, Koo Jeong Kang, Yun Shin Chun, Hee Jin Jang, Byoung Gill Lee, Hyun Goo Woo, Min Jin Ha, Rehan Akbani, Lewis R Roberts, David A Wheeler, Ju-Seog Lee



Hepatology, [Online ahead of print], doi:10.1002/hep.32490




ABSTRACT



Background & aims: While many studies revealed transcriptomic subtypes of hepatocellular carcinoma (HCC), concordance of the subtypes are not fully examined. We aim to examine consensus of transcriptomic subtypes and correlate them with clinical outcomes.

Approach and results: By integrating 16 previously established genomic signatures for HCC subtypes, we identified 5 clinically and molecularly distinct consensus subtypes. STM (STeM) is characterized by high stem cell features, vascular invasion, and poor prognosis. CIN (Chromosomal INstability) has moderate stem cell features but high genomic instability and low immune activity. IMH (IMmune High) is characterized by high immune activity. BCM (Beta-Catenin with high Male predominance) is characterized by prominent β-catenin activation, low miRNA expression, hypomethylation, and high sensitivity to sorafenib. DLP (Differentiated and Low Proliferation) is differentiated with high HNF4A activity. We also developed and validated a robust predictor of consensus subtype with 100 genes (PICS100) and demonstrated that 5 subtypes were well conserved in patient derived xenograft (PDX) models and cell lines. By analyzing serum proteomic data from the same patients, we further identified potential serum biomarkers that can stratify patients into subtypes.

Conclusions: Five HCC subtypes are correlated with genomic phenotypes and clinical outcomes and highly conserved in pre-clinical models, providing a framework for selecting the most appropriate models for preclinical studies.

Keywords: cancer immune activity; consensus subtypes; gene expression profile; hepatocellular carcinoma; liver cancer; patient derived xenograft model; sorafenib.

- PMID: 35349735


- Fulltext: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.32490